

EPICS

ASCO Conference Coverage – Focus on Breast Cancer (BC) Tuesday, June 13, 2022; 10.00 AM – 1.00 PM ET/16.00 – 19.00 CET

Chair: Adam Brufsky, MD, PhD (US)

Faculty

- Joyce O’Shaughnessy, MD (US)
- Peter Kaufman, MD (US)
- Mark Pegram, MD (US) - **TBC**
- Sara Tolaney MD, MPH (US) - **TBC**
- Guy Jerusalem, MD, PhD (Belgium)
- Giuseppe Curigliano, MD, PhD (Italy)
- Nadia Harbeck, MD, PhD (Germany)
- Joseph Gligorov, MD, PhD (France)

AGENDA – 3 hours

Time ET/CEST	Topic	Speaker/Moderator
10.00 AM – 10.05 AM 16.00 – 16.05 (5 min)	Welcome and Introductions	Adam Brufsky, MD, PhD
10.05 AM – 10.15 AM 16.05 – 16.15 (10 min)	New and Emerging Treatments in HER2+ BC: Early and Metastatic Early HER2+ BC <ul style="list-style-type: none"> • 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC). Javier Cortes, et al. LBA506 • Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial. Pier Franco Conte, et al. LBA637 • Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL. Rebecca Arielle Shatsk, et al. LBA612 	Joyce O’Shaughnessy, MD

<p>10.15 AM – 10.25 AM 16.15 – 16.25 (10 min)</p>	<p>New and Emerging Treatments in HER2+ BC: Early and Metastatic</p> <p>Metastatic HER2+ BC</p> <ul style="list-style-type: none"> • A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC). Erika Hamilton, et al. 1004 (oral) • An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03. Ian Krop, et al. 1006 (oral) • Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials. Robert Hills, et al. 508 (oral) • Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer. Carey K. Anders, et al. 1051 	<p>Giuseppe Curigliano, MD, PhD</p>
<p>10.25 AM – 11.00 AM 16.25 – 17.00 (35 min)</p>	<p>Discussion: HER2+ BC</p> <p>Early HER2+ BC</p> <ul style="list-style-type: none"> • Were there any practice-changing data presented at ASCO? • How do you view the data of treatment de-escalation in early-stage HER2+ BC? • What are your thoughts on the data from the early-stage, high-risk HER2+ BC population? • How do you see your treatment approaches in this setting changing in the next 2–3 years? <p>Metastatic HER2+ BC</p> <ul style="list-style-type: none"> • Were there any practice-changing data presented at ASCO? • What is the optimal sequencing of HER2-targeted agents in the metastatic setting? What drives the sequencing decisions? • How is real-world evidence of the use of anti-HER2 agents defining the treatment approaches in this setting? • Are there any ongoing studies in the HER2+ mBC setting that are particularly exciting or could be practice changing? 	<p>All</p>

<p>11.00 AM – 11.05 AM 17.00 – 17.05 (5 min)</p>	<p>Key Takeaways: HER2+ BC</p>	<p>Joyce O’Shaughnessy, MD, and Giuseppe Curigliano, MD, PhD</p>
<p>11.05 AM – 11.15 AM 17.05 – 17.15 (10 min)</p>	<p>New and Emerging Approaches in HR+, HER2– Early and Metastatic BC Early HER2– BC</p> <ul style="list-style-type: none"> • Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial. Lauren Brown, et al. 504 (oral) • Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 premenopausal women in 25 randomized trials. Richard Gray, et al. 503 (oral) • Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2– early breast cancer. Dennis Slamon, et al. LBA500 • Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC). Erika Hamilton, et al. 501 (oral) • HER2 negative breast cancer: Analysis from the PENELOPE-B trial. Nicholas Turner, et al. 502 (oral) 	<p>Mark Pegram, MD</p>
<p>11.15 AM – 11.30 AM 17.15 – 17.30 (15 min)</p>	<p>New and Emerging Approaches in HR+, HER2– Early and Metastatic BC Metastatic HER2– BC</p> <ul style="list-style-type: none"> • Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Gabe Sonke, et al. LBA1000 • Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC): Primary 	<p>Nadia Harbeck, MD, PhD</p>

	<p>results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial. Takahiro Kogawa, et al. LBA1068</p> <ul style="list-style-type: none"> • Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial. Antonio Llombart-Cussac, et al. LBA1001 • Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC). Sara Tolaney, et al. 1003 (oral) • Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial. Mafalda Oliveira, et al. 1066 • Interim analyses (IA) of the giredestrant (G), G + abemaciclib (A), and G + ribociclib (R) arms in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2-LA/mBC). Mafalda Oliveira, et al. 1061 	
<p>11.30 AM – 11.35 AM 17.30 – 17.35 (5 min)</p>	<p>BREAK</p>	
<p>11.35 AM – 12.15 PM 17.35 – 18.15 (40 min)</p>	<p>Discussion: HR+, HER2-</p> <p>Early HR+, HER2-</p> <ul style="list-style-type: none"> • In your opinion, what are the most impactful data in early-stage HR+, HER2- BC recently presented? • How do you determine which adjuvant or neoadjuvant therapy to use? • What are your thoughts on the data from the early-stage, high-risk HER2- BC population? <p>Metastatic HR+, HER2-</p> <ul style="list-style-type: none"> • In your opinion, what are the most impactful data in HR+, HER2- mBC recently presented? 	<p>All</p>

	<ul style="list-style-type: none"> • What is your current treatment strategy for HR+, HER2– mBC (first and later lines)? <ul style="list-style-type: none"> – How do you select between available CDK4/6 inhibitors? – How have the data from the adjuvant CDK4/6 inhibitor trials impacted your preference/use of CDK4/6 inhibitors in the metastatic setting, namely as first-line therapy? • What are your views on the data from the TROPiCS-02 study with sacituzumab govitecan, and what could be its role in HR+, HER2– mBC? • What are your thoughts on the data with oral SERDs in HR+, HER2– mBC? • What future agents/approaches are you most enthusiastic about? 	
12.15 PM – 12.20 PM 18.15 – 18.20 (5 min)	Key Takeaways: HR+, HER2– Early and Metastatic BC	Mark Pegram, MD, and Nadia Harbeck, MD, PhD
12.20 PM – 12.30 PM 18.20 – 18.30 (10 min)	Advances in Early and Metastatic Triple-Negative Breast Cancer (TNBC) <ul style="list-style-type: none"> • Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study. Jeremy Force, et al. 603 • Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies. Yael Bar, et al. 1005 (oral) • Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial. Shane Stecklein, et al. 507 (oral) • Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast). Juan De La Haba. 1093 • TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). Zefei Jiang, et al. LBA1013 	Sara Tolaney MD, MPH
12.30 PM – 12.50 PM 18.30 – 18.50	Discussion: TNBC	All

(20 min)	<ul style="list-style-type: none"> • In your opinion, what are the most impactful data in TNBC recently presented? • How do you see your treatment approaches in this setting changing in the next 2–3 years? • What future agents/approaches are you most enthusiastic about? 	
12.50 PM – 12.55 PM 18.50 – 18.55 (5 min)	Key Takeaways: TNBC	Sara Tolaney MD, MPH
12.55 PM – 1.00 PM 18.55 – 19.00 (5 min)	Meeting Close	Adam Brufsky, MD, PhD